+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Peptide-Drug Conjugates CDMO Service Market by Therapeutic Area (Cardiovascular, Immunology, Infectious Disease), Scale of Operation (Clinical, Commercial, Discovery), Service Offering, Peptide Type, End User - Global Forecast 2025-2030- Product Image
Peptide-Drug Conjugates CDMO Service Market by Therapeutic Area (Cardiovascular, Immunology, Infectious Disease), Scale of Operation (Clinical, Commercial, Discovery), Service Offering, Peptide Type, End User - Global Forecast 2025-2030- Product Image
New

Peptide-Drug Conjugates CDMO Service Market by Therapeutic Area (Cardiovascular, Immunology, Infectious Disease), Scale of Operation (Clinical, Commercial, Discovery), Service Offering, Peptide Type, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 193 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6119603
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The emergence of peptide-drug conjugates as a powerful therapeutic modality has ushered in a new era of precision medicine, where peptides deliver potent payloads with exceptional specificity. Advances in conjugation techniques and linker technologies have transformed the once-nascent field into a robust platform capable of addressing complex disease targets. In this dynamic environment, contract development and manufacturing organizations play a pivotal role, bridging the gap between discovery concepts and clinical realities.

During early development, meticulous peptide synthesis methods such as solid-phase and liquid-phase approaches lay the foundation for purity and yield, while process development efforts ensure scalability and reproducibility. As programs progress through clinical phases, stringent analytical services encompassing characterization, release testing, and stability assessments become indispensable for regulatory compliance. The seamless integration of formulation science, whether liquid or lyophilized, further refines drug product performance and patient experience.

By crafting a thoughtful introduction to these core capabilities, stakeholders gain a clear roadmap for orchestrating complex peptide-drug conjugate programs from inception through commercialization.

Exploring How Advances in Linker Chemistry and Peptide Engineering Are Driving End-to-End Service Evolution in CDMO Offerings

The peptide-drug conjugate landscape is undergoing transformative shifts, driven by innovations in peptide engineering and linker chemistry. Recent breakthroughs in cleavable and noncleavable linkers have unlocked versatile release profiles, enabling payloads to be delivered with unprecedented precision at disease sites. Meanwhile, advances in modified and peptidomimetic structures are enhancing in vivo stability, expanding the therapeutic window for challenging targets.

As immuno-oncology, infectious disease and cardiovascular programs gain momentum, CDMOs have evolved beyond traditional manufacturing to offer end-to-end service portfolios. Integrated workflows now encompass discovery support, where preclinical research benefits from advanced analytical characterization, through large-scale commercial manufacturing. This shift toward comprehensive service offerings reduces handoffs and streamlines timelines.

Strategic partnerships with CDMOs that demonstrate deep expertise in both upstream development and downstream process optimization will define the next wave of market leaders. Through these alliances, organizations can harness the collective momentum of technological progress and changing therapeutic priorities.

Assessing the Multifaceted Consequences of 2025 Tariff Policies on Peptide-Drug Conjugate Supply Chains and Cost Resilience

The enactment of new tariff regulations in 2025 has introduced a layer of complexity for peptide-drug conjugate programs reliant on global supply chains. Companies sourcing specialized reagents, consumables and instrumentation from international suppliers are now assessing cost implications and seeking strategies to mitigate duties. With particular scrutiny on raw materials crossing borders, the need to qualify alternate vendors and localize critical sourcing has never been more pronounced.

To adapt, organizations are diversifying procurement strategies, forging partnerships with regional suppliers in North America, Europe and Asia-Pacific to balance cost efficiency with supply continuity. Simultaneously, CDMOs are reinforcing in-house capabilities for peptide synthesis, conjugation and analytical testing to reduce dependence on external vendors, thereby insulating operations from future tariff fluctuations.

The cumulative impact of these regulatory shifts underscores the strategic imperative to design resilient supply chains and agile manufacturing footprints that can absorb financial pressures while maintaining program momentum.

Illuminating Complex Development and Manufacturing Segmentations to Reveal How Diverse Factors Shape Peptide-Drug Conjugate Program Strategies

A deep dive into segmentation reveals that therapeutic targeting shapes the development landscape, with cardiovascular initiatives addressing atherosclerosis and heart failure while immunology programs focus on autoimmune diseases and inflammatory disorders. Infectious disease pipelines span bacterial infection and viral infection, and oncology efforts tackle both hematological malignancies and solid tumors. Across discovery, clinical and commercial scales of operation, phase I through phase III endeavors intersect with preclinical research, pilot studies and large-scale manufacturing, illustrating the continuum of program progression.

Service offerings further refine the ecosystem, where analytical services deliver essential characterization, release testing and stability evaluations, and process development integrates upstream and downstream optimization. Conjugation expertise in cleavable and noncleavable linkers dovetails with formulation strategies spanning liquid to lyophilized presentations. Peptide synthesis modalities, whether liquid phase or solid phase, align with customized process development to meet unique project demands. Meanwhile, the diversity of peptide types-from cyclic and linear to modified structures and peptidomimetics-caters to distinct pharmacological objectives.

End users ranging from academic institutions and government agencies to biotech firms, pharmaceutical companies and contract research organizations engage CDMOs to access specialized capabilities, forging collaborative pathways that underpin innovation across every segment.

Unveiling How Regional Regulatory, Investment, and Infrastructure Dynamics Drive Distinct Peptide-Drug Conjugate CDMO Collaboration Models Globally

Regional dynamics in the Americas emphasize strong infrastructural networks, robust regulatory frameworks and a dense landscape of biotech hubs, driving demand for comprehensive CDMO support from discovery through commercial operations. In Europe, Middle East & Africa, the emphasis on regulatory harmonization and cost-effective solutions spurs collaboration between innovators and service providers, with emerging markets fueling interest in scalable process development. Asia-Pacific reflects rapid expansion in manufacturing capacity, bolstered by strategic investments in high-throughput peptide synthesis and analytical platforms, as well as increasing governmental incentives for pharmaceutical innovation.

Across all regions, the interplay between regulatory rigor, technological advancement and investment climates shapes program prioritization and partner selection. By understanding these regional nuances, stakeholders can optimize site selection, risk management and go-to-market strategies to align with local strengths and address specific challenges.

Examining How Leading CDMO Organizations Establish Competitive Edge Through Technological Mastery, Strategic Expansion, and Client-Centric Services

Leading service providers are differentiating through specialized technical proficiencies, strategic global footprints and integrated service portfolios. Some excel in pioneering conjugation chemistries and peptide synthesis platforms, establishing center-of-excellence models that attract complex oncology and immunology programs. Others focus on scaling high-throughput analytical operations, enabling rapid characterization essential for early-stage decision-making.

Several CDMOs are strengthening their upstream and downstream process development by investing in modular, single-use bioprocessing technologies. This approach enhances flexibility, reduces contamination risk and accelerates campaign turnarounds. Moreover, strategic acquisitions and alliances are enabling providers to broaden their service scope, incorporate cutting-edge formulation capabilities and expand their geographic reach to better serve global clients.

Through a combination of innovation, capacity expansion and client-centric service models, these key companies are redefining the benchmarks for reliability, speed and regulatory compliance in peptide-drug conjugate manufacturing.

Strategic Collaboration, Digital Integration, and Supply Chain Resilience as Pillars for Driving Peptide-Drug Conjugate Program Success Across Development Stages

Industry leaders should prioritize co-development partnerships that align scientific expertise with tailored service models, ensuring seamless transitions from discovery through commercial launch. By embedding cross-functional project teams early, stakeholders can accelerate knowledge transfer, reduce technical risks and maintain momentum across phases. Concurrently, implementing digital solutions for real-time data analytics and process monitoring will enhance decision-making and quality oversight.

To fortify supply chain resilience, organizations must qualify multiple sourcing channels for critical reagents and engage in vendor risk assessments that anticipate regulatory changes. Embracing modular manufacturing approaches, such as single-use systems and flexible cleanroom designs, will facilitate rapid scale adjustments in response to clinical outcomes and market demands.

Finally, investing in talent development programs that foster specialized skill sets in peptide chemistry, analytical science and regulatory affairs will ensure that teams remain agile and equipped to navigate emerging challenges.

Rigorous Multi-Dimensional Methodology Leveraging Primary Expert Insights and Comprehensive Data Triangulation for Robust Market Analysis

This research integrates primary interviews with industry leaders, scientific experts and regulatory authorities to capture nuanced perspectives on technical trends, operational challenges and strategic priorities. Secondary sources such as peer-reviewed journals, patent filings and conference proceedings were systematically analyzed to validate emerging technologies and service innovations.

Data triangulation methods were employed to cross-verify qualitative insights with quantitative observations, ensuring comprehensive coverage of development modalities, supply chain dynamics and regional variations. The study’s framework categorizes findings according to therapeutic focus, scale of operation, service type, peptide composition and end-user profile, facilitating a multi-dimensional analysis of the ecosystem.

Rigorous quality control measures, including iterative reviews by subject matter experts, underpin the credibility of the conclusions and recommendations. In doing so, this methodology provides stakeholders with a robust foundation for strategic planning and operational optimization in peptide-drug conjugate CDMO engagements.

Synthesizing Key Themes to Illustrate How Integrated Partnerships, Technological Evolution, and Regional Strategies Shape the Future of Peptide-Drug Conjugate Development

As the peptide-drug conjugate field matures, the convergence of novel chemistries, advanced manufacturing technologies and dynamic regulatory landscapes will continue to redefine the contours of therapeutic development. Robust CDMO partnerships that integrate deep technical acumen with adaptable service models will be instrumental in translating innovative modalities into clinical realities.

Stakeholders who embrace end-to-end collaboration, invest in supply chain robustness and harness real-time analytics will be best positioned to overcome the complexities of scale-up and regulatory hurdles. Moreover, understanding regional nuances and aligning strategic capabilities to local ecosystems will unlock new pathways to efficiency and market access.

In this evolving environment, sustained investment in talent, process innovation and strategic alliances will underpin long-term success, ensuring that peptide-drug conjugates fulfill their promise in addressing unmet medical needs.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Therapeutic Area
    • Cardiovascular
      • Atherosclerosis
      • Heart Failure
    • Immunology
      • Autoimmune Diseases
      • Inflammatory Disorders
    • Infectious Disease
      • Bacterial Infection
      • Viral Infection
    • Oncology
      • Hematological Malignancies
      • Solid Tumors
  • Scale Of Operation
    • Clinical
      • Phase I
      • Phase II
      • Phase III
    • Commercial
      • Large Scale Manufacturing
      • Small Scale Manufacturing
    • Discovery
      • Preclinical Research
    • Pilot
  • Service Offering
    • Analytical Services
      • Characterization
      • Release Testing
      • Stability Testing
    • Conjugation
      • Cleavable Linkers
      • Noncleavable Linkers
    • Formulation
      • Liquid
      • Lyophilized
    • Peptide Synthesis
      • Liquid Phase
      • Solid Phase
    • Process Development
      • Downstream
      • Upstream
  • Peptide Type
    • Cyclic
    • Linear
    • Modified
    • Peptidomimetics
  • End User
    • Academic
    • Biotechnology
    • Contract Research Organization
    • Government
    • Pharmaceutical
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:

  • Lonza Group AG
  • Catalent, Inc.
  • Thermo Fisher Scientific Inc.
  • WuXi AppTec Co., Ltd.
  • Polypeptide Group GmbH
  • Bachem Holding AG
  • Evotec SE
  • CordenPharma International GmbH
  • Recipharm AB
  • GenScript Biotech Corporation

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Rapid adoption of site-specific peptide conjugation techniques enabling higher drug stability and targeted delivery
5.2. Integration of continuous flow peptide synthesis platforms to accelerate conjugate production timelines
5.3. Customization of bioconjugation linkers for improved in vivo stability and controlled payload release kinetics
5.4. Strategic partnerships between peptide CDMOs and biopharma firms to enable turnkey ADC-like development services
5.5. Regulatory alignment initiatives driving global harmonization of quality standards for peptide-drug conjugate manufacturing
5.6. Adoption of advanced analytics and PAT tools for real-time monitoring of peptide-drug conjugation processes
5.7. Scale-up challenges and solutions for cGMP production of complex peptide-drug conjugates at commercial volumes
5.8. Emergence of sustainable and green chemistry methods in peptide conjugate manufacturing reducing environmental impact
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Peptide-Drug Conjugates CDMO Service Market, by Therapeutic Area
8.1. Introduction
8.2. Cardiovascular
8.2.1. Atherosclerosis
8.2.2. Heart Failure
8.3. Immunology
8.3.1. Autoimmune Diseases
8.3.2. Inflammatory Disorders
8.4. Infectious Disease
8.4.1. Bacterial Infection
8.4.2. Viral Infection
8.5. Oncology
8.5.1. Hematological Malignancies
8.5.2. Solid Tumors
9. Peptide-Drug Conjugates CDMO Service Market, by Scale Of Operation
9.1. Introduction
9.2. Clinical
9.2.1. Phase I
9.2.2. Phase II
9.2.3. Phase III
9.3. Commercial
9.3.1. Large Scale Manufacturing
9.3.2. Small Scale Manufacturing
9.4. Discovery
9.4.1. Preclinical Research
9.5. Pilot
10. Peptide-Drug Conjugates CDMO Service Market, by Service Offering
10.1. Introduction
10.2. Analytical Services
10.2.1. Characterization
10.2.2. Release Testing
10.2.3. Stability Testing
10.3. Conjugation
10.3.1. Cleavable Linkers
10.3.2. Noncleavable Linkers
10.4. Formulation
10.4.1. Liquid
10.4.2. Lyophilized
10.5. Peptide Synthesis
10.5.1. Liquid Phase
10.5.2. Solid Phase
10.6. Process Development
10.6.1. Downstream
10.6.2. Upstream
11. Peptide-Drug Conjugates CDMO Service Market, by Peptide Type
11.1. Introduction
11.2. Cyclic
11.3. Linear
11.4. Modified
11.5. Peptidomimetics
12. Peptide-Drug Conjugates CDMO Service Market, by End User
12.1. Introduction
12.2. Academic
12.3. Biotechnology
12.4. Contract Research Organization
12.5. Government
12.6. Pharmaceutical
13. Americas Peptide-Drug Conjugates CDMO Service Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Peptide-Drug Conjugates CDMO Service Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Peptide-Drug Conjugates CDMO Service Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Lonza Group AG
16.3.2. Catalent, Inc.
16.3.3. Thermo Fisher Scientific Inc.
16.3.4. WuXi AppTec Co., Ltd.
16.3.5. Polypeptide Group GmbH
16.3.6. Bachem Holding AG
16.3.7. Evotec SE
16.3.8. CordenPharma International GmbH
16.3.9. Recipharm AB
16.3.10. GenScript Biotech Corporation
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2030 (%)
FIGURE 6. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SCALE OF OPERATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SCALE OF OPERATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SERVICE OFFERING, 2024 VS 2030 (%)
FIGURE 10. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SERVICE OFFERING, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PEPTIDE TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PEPTIDE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET: RESEARCHAI
FIGURE 26. PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET: RESEARCHSTATISTICS
FIGURE 27. PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET: RESEARCHCONTACTS
FIGURE 28. PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ATHEROSCLEROSIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ATHEROSCLEROSIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY HEART FAILURE, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CARDIOVASCULAR, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CARDIOVASCULAR, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY INFLAMMATORY DISORDERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY INFLAMMATORY DISORDERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY IMMUNOLOGY, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY IMMUNOLOGY, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY BACTERIAL INFECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY BACTERIAL INFECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY VIRAL INFECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY VIRAL INFECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY INFECTIOUS DISEASE, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SOLID TUMORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SCALE OF OPERATION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SCALE OF OPERATION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CLINICAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CLINICAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PHASE I, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PHASE I, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PHASE II, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PHASE II, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PHASE III, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PHASE III, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CLINICAL, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CLINICAL, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY COMMERCIAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY COMMERCIAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY LARGE SCALE MANUFACTURING, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY LARGE SCALE MANUFACTURING, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SMALL SCALE MANUFACTURING, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SMALL SCALE MANUFACTURING, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY COMMERCIAL, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY COMMERCIAL, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY DISCOVERY, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY DISCOVERY, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PRECLINICAL RESEARCH, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PRECLINICAL RESEARCH, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY DISCOVERY, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY DISCOVERY, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PILOT, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PILOT, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SERVICE OFFERING, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SERVICE OFFERING, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ANALYTICAL SERVICES, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ANALYTICAL SERVICES, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CHARACTERIZATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CHARACTERIZATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY RELEASE TESTING, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY RELEASE TESTING, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY STABILITY TESTING, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY STABILITY TESTING, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ANALYTICAL SERVICES, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CONJUGATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CONJUGATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CLEAVABLE LINKERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CLEAVABLE LINKERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY NONCLEAVABLE LINKERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY NONCLEAVABLE LINKERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CONJUGATION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CONJUGATION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY FORMULATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY FORMULATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY LIQUID, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY LIQUID, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY LYOPHILIZED, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY LYOPHILIZED, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PEPTIDE SYNTHESIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PEPTIDE SYNTHESIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY LIQUID PHASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY LIQUID PHASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SOLID PHASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SOLID PHASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PEPTIDE SYNTHESIS, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PEPTIDE SYNTHESIS, 2025-2030 (USD MILLION)
TABLE 107. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PROCESS DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 108. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PROCESS DEVELOPMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 109. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY DOWNSTREAM, BY REGION, 2018-2024 (USD MILLION)
TABLE 110. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY DOWNSTREAM, BY REGION, 2025-2030 (USD MILLION)
TABLE 111. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY UPSTREAM, BY REGION, 2018-2024 (USD MILLION)
TABLE 112. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY UPSTREAM, BY REGION, 2025-2030 (USD MILLION)
TABLE 113. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2024 (USD MILLION)
TABLE 114. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PROCESS DEVELOPMENT, 2025-2030 (USD MILLION)
TABLE 115. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PEPTIDE TYPE, 2018-2024 (USD MILLION)
TABLE 116. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PEPTIDE TYPE, 2025-2030 (USD MILLION)
TABLE 117. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CYCLIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 118. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CYCLIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 119. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY LINEAR, BY REGION, 2018-2024 (USD MILLION)
TABLE 120. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY LINEAR, BY REGION, 2025-2030 (USD MILLION)
TABLE 121. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY MODIFIED, BY REGION, 2018-2024 (USD MILLION)
TABLE 122. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY MODIFIED, BY REGION, 2025-2030 (USD MILLION)
TABLE 123. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PEPTIDOMIMETICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 124. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PEPTIDOMIMETICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 125. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 126. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 127. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ACADEMIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 128. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ACADEMIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 129. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY BIOTECHNOLOGY, BY REGION, 2018-2024 (USD MILLION)
TABLE 130. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY BIOTECHNOLOGY, BY REGION, 2025-2030 (USD MILLION)
TABLE 131. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 132. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 133. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY GOVERNMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 134. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY GOVERNMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 135. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PHARMACEUTICAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 136. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PHARMACEUTICAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 137. AMERICAS PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 138. AMERICAS PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 139. AMERICAS PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CARDIOVASCULAR, 2018-2024 (USD MILLION)
TABLE 140. AMERICAS PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CARDIOVASCULAR, 2025-2030 (USD MILLION)
TABLE 141. AMERICAS PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY IMMUNOLOGY, 2018-2024 (USD MILLION)
TABLE 142. AMERICAS PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY IMMUNOLOGY, 2025-2030 (USD MILLION)
TABLE 143. AMERICAS PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2024 (USD MILLION)
TABLE 144. AMERICAS PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY INFECTIOUS DISEASE, 2025-2030 (USD MILLION)
TABLE 145. AMERICAS PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 146. AMERICAS PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 147. AMERICAS PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SCALE OF OPERATION, 2018-2024 (USD MILLION)
TABLE 148. AMERICAS PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SCALE OF OPERATION, 2025-2030 (USD MILLION)
TABLE 149. AMERICAS PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CLINICAL, 2018-2024 (USD MILLION)
TABLE 150. AMERICAS PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CLINICAL, 2025-2030 (USD MILLION)
TABLE 151. AMERICAS PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY COMMERCIAL, 2018-2024 (USD MILLION)
TABLE 152. AMERICAS PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY COMMERCIAL, 2025-2030 (USD MILLION)
TABLE 153. AMERICAS PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY DISCOVERY, 2018-2024 (USD MILLION)
TABLE 154. AMERICAS PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY DISCOVERY, 2025-2030 (USD MILLION)
TABLE 155. AMERICAS PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SERVICE OFFERING, 2018-2024 (USD MILLION)
TABLE 156. AMERICAS PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SERVICE OFFERING, 2025-2030 (USD MILLION)
TABLE 157. AMERICAS PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2024 (USD MILLION)
TABLE 158. AMERICAS PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ANALYTICAL SERVICES, 2025-2030 (USD MILLION)
TABLE 159. AMERICAS PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CONJUGATION, 2018-2024 (USD MILLION)
TABLE 160. AMERICAS PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CONJUGATION, 2025-2030 (USD MILLION)
TABLE 161. AMERICAS PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 162. AMERICAS PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 163. AMERICAS PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PEPTIDE SYNTHESIS, 2018-2024 (USD MILLION)
TABLE 164. AMERICAS PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PEPTIDE SYNTHESIS, 2025-2030 (USD MILLION)
TABLE 165. AMERICAS PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2024 (USD MILLION)
TABLE 166. AMERICAS PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PROCESS DEVELOPMENT, 2025-2030 (USD MILLION)
TABLE 167. AMERICAS PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PEPTIDE TYPE, 2018-2024 (USD MILLION)
TABLE 168. AMERICAS PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PEPTIDE TYPE, 2025-2030 (USD MILLION)
TABLE 169. AMERICAS PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 170. AMERICAS PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 171. AMERICAS PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 172. AMERICAS PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 173. UNITED STATES PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 174. UNITED STATES PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 175. UNITED STATES PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CARDIOVASCULAR, 2018-2024 (USD MILLION)
TABLE 176. UNITED STATES PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CARDIOVASCULAR, 2025-2030 (USD MILLION)
TABLE 177. UNITED STATES PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY IMMUNOLOGY, 2018-2024 (USD MILLION)
TABLE 178. UNITED STATES PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY IMMUNOLOGY, 2025-2030 (USD MILLION)
TABLE 179. UNITED STATES PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2024 (USD MILLION)
TABLE 180. UNITED STATES PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY INFECTIOUS DISEASE, 2025-2030 (USD MILLION)
TABLE 181. UNITED STATES PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 182. UNITED STATES PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 183. UNITED STATES PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SCALE OF OPERATION, 2018-2024 (USD MILLION)
TABLE 184. UNITED STATES PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SCALE OF OPERATION, 2025-2030 (USD MILLION)
TABLE 185. UNITED STATES PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CLINICAL, 2018-2024 (USD MILLION)
TABLE 186. UNITED STATES PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CLINICAL, 2025-2030 (USD MILLION)
TABLE 187. UNITED STATES PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY COMMERCIAL, 2018-2024 (USD MILLION)
TABLE 188. UNITED STATES PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY COMMERCIAL, 2025-2030 (USD MILLION)
TABLE 189. UNITED STATES PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY DISCOVERY, 2018-2024 (USD MILLION)
TABLE 190. UNITED STATES PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY DISCOVERY, 2025-2030 (USD MILLION)
TABLE 191. UNITED STATES PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SERVICE OFFERING, 2018-2024 (USD MILLION)
TABLE 192. UNITED STATES PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SERVICE OFFERING, 2025-2030 (USD MILLION)
TABLE 193. UNITED STATES PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2024 (USD MILLION)
TABLE 194. UNITED STATES PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ANALYTICAL SERVICES, 2025-2030 (USD MILLION)
TABLE 195. UNITED STATES PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CONJUGATION, 2018-2024 (USD MILLION)
TABLE 196. UNITED STATES PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CONJUGATION, 2025-2030 (USD MILLION)
TABLE 197. UNITED STATES PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 198. UNITED STATES PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 199. UNITED STATES PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PEPTIDE SYNTHESIS, 2018-2024 (USD MILLION)
TABLE 200. UNITED STATES PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PEPTIDE SYNTHESIS, 2025-2030 (USD MILLION)
TABLE 201. UNITED STATES PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2024 (USD MILLION)
TABLE 202. UNITED STATES PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PROCESS DEVELOPMENT, 2025-2030 (USD MILLION)
TABLE 203. UNITED STATES PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PEPTIDE TYPE, 2018-2024 (USD MILLION)
TABLE 204. UNITED STATES PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PEPTIDE TYPE, 2025-2030 (USD MILLION)
TABLE 205. UNITED STATES PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 206. UNITED STATES PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 207. UNITED STATES PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 208. UNITED STATES PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 209. CANADA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 210. CANADA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 211. CANADA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CARDIOVASCULAR, 2018-2024 (USD MILLION)
TABLE 212. CANADA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CARDIOVASCULAR, 2025-2030 (USD MILLION)
TABLE 213. CANADA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY IMMUNOLOGY, 2018-2024 (USD MILLION)
TABLE 214. CANADA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY IMMUNOLOGY, 2025-2030 (USD MILLION)
TABLE 215. CANADA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2024 (USD MILLION)
TABLE 216. CANADA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY INFECTIOUS DISEASE, 2025-2030 (USD MILLION)
TABLE 217. CANADA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 218. CANADA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 219. CANADA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SCALE OF OPERATION, 2018-2024 (USD MILLION)
TABLE 220. CANADA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SCALE OF OPERATION, 2025-2030 (USD MILLION)
TABLE 221. CANADA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CLINICAL, 2018-2024 (USD MILLION)
TABLE 222. CANADA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CLINICAL, 2025-2030 (USD MILLION)
TABLE 223. CANADA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY COMMERCIAL, 2018-2024 (USD MILLION)
TABLE 224. CANADA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY COMMERCIAL, 2025-2030 (USD MILLION)
TABLE 225. CANADA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY DISCOVERY, 2018-2024 (USD MILLION)
TABLE 226. CANADA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY DISCOVERY, 2025-2030 (USD MILLION)
TABLE 227. CANADA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SERVICE OFFERING, 2018-2024 (USD MILLION)
TABLE 228. CANADA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SERVICE OFFERING, 2025-2030 (USD MILLION)
TABLE 229. CANADA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2024 (USD MILLION)
TABLE 230. CANADA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ANALYTICAL SERVICES, 2025-2030 (USD MILLION)
TABLE 231. CANADA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CONJUGATION, 2018-2024 (USD MILLION)
TABLE 232. CANADA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CONJUGATION, 2025-2030 (USD MILLION)
TABLE 233. CANADA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 234. CANADA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 235. CANADA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PEPTIDE SYNTHESIS, 2018-2024 (USD MILLION)
TABLE 236. CANADA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PEPTIDE SYNTHESIS, 2025-2030 (USD MILLION)
TABLE 237. CANADA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2024 (USD MILLION)
TABLE 238. CANADA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PROCESS DEVELOPMENT, 2025-2030 (USD MILLION)
TABLE 239. CANADA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PEPTIDE TYPE, 2018-2024 (USD MILLION)
TABLE 240. CANADA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PEPTIDE TYPE, 2025-2030 (USD MILLION)
TABLE 241. CANADA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 242. CANADA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 243. MEXICO PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 244. MEXICO PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 245. MEXICO PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CARDIOVASCULAR, 2018-2024 (USD MILLION)
TABLE 246. MEXICO PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CARDIOVASCULAR, 2025-2030 (USD MILLION)
TABLE 247. MEXICO PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY IMMUNOLOGY, 2018-2024 (USD MILLION)
TABLE 248. MEXICO PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY IMMUNOLOGY, 2025-2030 (USD MILLION)
TABLE 249. MEXICO PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2024 (USD MILLION)
TABLE 250. MEXICO PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY INFECTIOUS DISEASE, 2025-2030 (USD MILLION)
TABLE 251. MEXICO PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 252. MEXICO PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 253. MEXICO PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SCALE OF OPERATION, 2018-2024 (USD MILLION)
TABLE 254. MEXICO PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SCALE OF OPERATION, 2025-2030 (USD MILLION)
TABLE 255. MEXICO PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CLINICAL, 2018-2024 (USD MILLION)
TABLE 256. MEXICO PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CLINICAL, 2025-2030 (USD MILLION)
TABLE 257. MEXICO PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY COMMERCIAL, 2018-2024 (USD MILLION)
TABLE 258. MEXICO PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY COMMERCIAL, 2025-2030 (USD MILLION)
TABLE 259. MEXICO PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY DISCOVERY, 2018-2024 (USD MILLION)
TABLE 260. MEXICO PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY DISCOVERY, 2025-2030 (USD MILLION)
TABLE 261. MEXICO PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SERVICE OFFERING, 2018-2024 (USD MILLION)
TABLE 262. MEXICO PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SERVICE OFFERING, 2025-2030 (USD MILLION)
TABLE 263. MEXICO PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2024 (USD MILLION)
TABLE 264. MEXICO PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ANALYTICAL SERVICES, 2025-2030 (USD MILLION)
TABLE 265. MEXICO PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CONJUGATION, 2018-2024 (USD MILLION)
TABLE 266. MEXICO PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CONJUGATION, 2025-2030 (USD MILLION)
TABLE 267. MEXICO PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 268. MEXICO PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 269. MEXICO PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PEPTIDE SYNTHESIS, 2018-2024 (USD MILLION)
TABLE 270. MEXICO PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PEPTIDE SYNTHESIS, 2025-2030 (USD MILLION)
TABLE 271. MEXICO PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2024 (USD MILLION)
TABLE 272. MEXICO PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PROCESS DEVELOPMENT, 2025-2030 (USD MILLION)
TABLE 273. MEXICO PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PEPTIDE TYPE, 2018-2024 (USD MILLION)
TABLE 274. MEXICO PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PEPTIDE TYPE, 2025-2030 (USD MILLION)
TABLE 275. MEXICO PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 276. MEXICO PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 277. BRAZIL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 278. BRAZIL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 279. BRAZIL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CARDIOVASCULAR, 2018-2024 (USD MILLION)
TABLE 280. BRAZIL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CARDIOVASCULAR, 2025-2030 (USD MILLION)
TABLE 281. BRAZIL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY IMMUNOLOGY, 2018-2024 (USD MILLION)
TABLE 282. BRAZIL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY IMMUNOLOGY, 2025-2030 (USD MILLION)
TABLE 283. BRAZIL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2024 (USD MILLION)
TABLE 284. BRAZIL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY INFECTIOUS DISEASE, 2025-2030 (USD MILLION)
TABLE 285. BRAZIL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 286. BRAZIL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 287. BRAZIL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SCALE OF OPERATION, 2018-2024 (USD MILLION)
TABLE 288.

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Peptide-Drug Conjugates CDMO Service market report include:
  • Lonza Group AG
  • Catalent, Inc.
  • Thermo Fisher Scientific Inc.
  • WuXi AppTec Co., Ltd.
  • Polypeptide Group GmbH
  • Bachem Holding AG
  • Evotec SE
  • CordenPharma International GmbH
  • Recipharm AB
  • GenScript Biotech Corporation

Related Topics

Related Reports

Peptide API CDMO Services Market by Type, Category, Manufacturing Process, Application, End User - Global Forecast to 2030 - Product Image

Peptide API CDMO Services Market by Type, Category, Manufacturing Process, Application, End User - Global Forecast to 2030

  • Report
  • 194 Pages
  • Global
From
Peptide and Oligonucleotide CDMO - Global Strategic Business Report - Product Image

Peptide and Oligonucleotide CDMO - Global Strategic Business Report

  • Report
  • 370 Pages
  • Global
From
Peptide and Oligonucleotide CDMO Market Report: Trends, Forecast and Competitive Analysis to 2030 - Product Image

Peptide and Oligonucleotide CDMO Market Report: Trends, Forecast and Competitive Analysis to 2030

  • Report
  • 150 Pages
  • Global
From
Antibody Drug Conjugates Contract Manufacturing Market by Type (Clinical, Commercial), Service Offered (End-to-End Manufacturing, Standalone / Modular Services), Payload Type, Linker Type, Application - Global Forecast 2025-2030 - Product Image

Antibody Drug Conjugates Contract Manufacturing Market by Type (Clinical, Commercial), Service Offered (End-to-End Manufacturing, Standalone / Modular Services), Payload Type, Linker Type, Application - Global Forecast 2025-2030

  • Report
  • 193 Pages
  • Global
From
Peptide and Oligonucleotide CDMO Market Report 2025 - Product Image

Peptide and Oligonucleotide CDMO Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.